<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04128969</url>
  </required_header>
  <id_info>
    <org_study_id>H-45557</org_study_id>
    <secondary_id>R01HL148217</secondary_id>
    <nct_id>NCT04128969</nct_id>
  </id_info>
  <brief_title>Causal Mechanisms in Adolescent Arterial Stiffness</brief_title>
  <official_title>Causal Mechanisms in Adolescent Arterial Stiffness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hardening of the blood vessels, called arterial stiffness, is a risk factor for future heart&#xD;
      disease and its causes are unclear. The proposed study will 1) randomly assign adolescents at&#xD;
      high risk of stiffening blood vessels to take a protein supplement called carnitine and study&#xD;
      its effects on arterial stiffening and 2) study carnitine related genes for their effect on&#xD;
      arterial stiffening. The study will definitively establish a role for carnitine action as a&#xD;
      cause of stiffening blood vessels and signal a way to treat or prevent stiffening.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aortic stiffness measured in adolescence or adulthood determines current hypertension,&#xD;
      predicts future incidence of hypertension, and future atherosclerotic cardiovascular disease&#xD;
      (ASCVD) events. International hypertension guidelines list severe aortic stiffness as grounds&#xD;
      to intensify anti-hypertensive pharmacotherapy. Mechanisms of arterial stiffness beyond aging&#xD;
      and obesity warrant further elucidation. In our preliminary data from adolescents attending&#xD;
      weight-loss summer camps arterial stiffness improvement was not associated with weight change&#xD;
      but was with change in circulating carnitine. Carnitine influences fatty acid oxidation and&#xD;
      carbohydrate metabolism. Carnitine could therefore link to arterial stiffness through insulin&#xD;
      resistance which in turn affects cellular tone, vascular fibrosis, modification of lipids or&#xD;
      glucose metabolism, and/or advanced glycation end products. This proposal leverages 2&#xD;
      instrumental variable study designs to infer a causal relation between carnitine and arterial&#xD;
      stiffness. First, in 166 adolescents at risk of arterial stiffening due to high serum&#xD;
      triglycerides(TG), we will conduct a mechanistic, double blinded, randomized controlled trial&#xD;
      for the effect of 6 months of oral carnitine supplementation (CS+, n=83) versus placebo (CS-,&#xD;
      n=83) on aortic stiffness measured as carotid femoral pulse wave velocity (CFPWV); serum&#xD;
      fatty acid oxidation biomarkers by metabolomics analysis; insulin resistance as homeostatic&#xD;
      model assessment of insulin resistance (HOMA-IR); and TG. Aim 1 is to compare CS+ versus CS-&#xD;
      on change in arterial stiffness and monitor adverse events. The hypothesis CS+ is associated&#xD;
      with lower arterial stiffening, and CS+ effect is not modified by sex or race/ethnicity. Aim&#xD;
      2 is to compare the effect of CS+ versus CS- on fatty acid metabolism, insulin resistance,&#xD;
      and lipids. The hypothesis is that CS+ alters long chain fatty acid beta oxidation, measured&#xD;
      as lower long chain acylcarnitines, which in turn improves (HOMA-IR), and in turn decreases&#xD;
      TG levels. This causal chain will be disentangled for direct versus indirect effects on CFPWV&#xD;
      change. Second, naturally randomly assorted carnitine single nucleotide polymorphisms (SNPs)&#xD;
      noted above will be used to characterize the relationship of carnitine to arterial stiffness&#xD;
      and stratify the effectiveness of CS+.Aim 3a is to obtain the direct effect of carnitine on&#xD;
      arterial stiffness using Mendelian randomization of SNPs associated with serum carnitine as&#xD;
      instrumental variables with the hypothesis these variant SNPs are associated with lower&#xD;
      arterial stiffness, supporting a causal inference. Aim 3b is to identify effect modification&#xD;
      of CS+ vs CS- on arterial stiffness by examining if a carnitine genetic risk score will&#xD;
      modify the effect of CS+ on change in arterial stiffness. This proposal with 2 instrumental&#xD;
      variable projects would evaluate a causal role for carnitine in arterial stiffness at a point&#xD;
      when the life course trajectory to hypertension can be modified. The study will also&#xD;
      investigate the role of carnitine in insulin resistance and dyslipidemia at this same age,&#xD;
      which may serve as grounds for future therapeutic clinical trials. Discovering genetically&#xD;
      mediated causes of arterial stiffness or other outcomes may facilitate targeting of future&#xD;
      therapies on susceptible youth before atherosclerotic changes are irreversible.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Carotid Femoral Pulse Wave Velocity</measure>
    <time_frame>6 months</time_frame>
    <description>Carotid Femoral Pulse Wave Velocity will be measured noninvasively using applanation tonometry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Triglyceride</measure>
    <time_frame>6 months</time_frame>
    <description>Fasting serum triglycerides to be measured using conventional techniques.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Resistance</measure>
    <time_frame>6 month</time_frame>
    <description>Insulin resistance will be assessed using fasting serum glucose and fasting serum insulin to calculate homeostatic model assessment of insulin resistance.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Lipid Disorder</condition>
  <condition>Dyslipidemias</condition>
  <condition>Aortic Stiffness</condition>
  <condition>Insulin Resistance Syndrome</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Pediatric Obesity</condition>
  <arm_group>
    <arm_group_label>Carnitine supplementation (CS+)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carnitine supplementation in liquid form, sugar free.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (CS-)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator liquid similar in appearance and taste to CS+.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CS+</intervention_name>
    <description>Oral carnitine supplementation</description>
    <arm_group_label>Carnitine supplementation (CS+)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CS-</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo (CS-)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 13-19 year old adolescents&#xD;
&#xD;
          2. males and females&#xD;
&#xD;
          3. all ethnicities and races&#xD;
&#xD;
          4. fasting serum triglyceride levels over 130 and less than 500 mg/dL&#xD;
&#xD;
          5. fasting low density lipoprotein cholesterol (LDL-C) less than 160mg/dL.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. known seizure disorder&#xD;
&#xD;
          2. renal failure patients requiring renal replacement therapy like dialysis or renal&#xD;
             transplant&#xD;
&#xD;
          3. diabetes mellitus type 1 or 2&#xD;
&#xD;
          4. congenital heart disease requiring surgical or catheterization intervention&#xD;
&#xD;
          5. current pregnancy or planned pregnancy during the active study participation&#xD;
&#xD;
          6. incarceration/institutionalized/wards of the state&#xD;
&#xD;
          7. known metabolic disorders that require carnitine therapy&#xD;
&#xD;
          8. nonadherence to study protocol during run-in phase defined as possessing 25% more than&#xD;
             the expected remainder of placebo supplement pro-rated to the day of assessment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Justin P Zachariah, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra Pena, CCRP</last_name>
    <phone>832-826-2806</phone>
    <email>sypena@texaschildrens.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Garuba</last_name>
    <phone>832-826-5925</phone>
    <email>garuba@bcm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Wisor, MPH</last_name>
      <phone>832-826-5925</phone>
      <email>sarah.wisor@bcm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Justin Zachariah, MD MPH</last_name>
      <phone>832-826-1280</phone>
      <email>justin.zachariah@bcm.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>August 7, 2021</last_update_submitted>
  <last_update_submitted_qc>August 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Justin Zachariah</investigator_full_name>
    <investigator_title>Principal Investigator. Assistant Professor in Pediatrics</investigator_title>
  </responsible_party>
  <keyword>dyslipidemia</keyword>
  <keyword>arterial stiffness</keyword>
  <keyword>pediatric obesity</keyword>
  <keyword>metabolic syndrome</keyword>
  <keyword>insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Pediatric Obesity</mesh_term>
    <mesh_term>Lipid Metabolism Disorders</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

